Netupitant & Palonosetron
- TRADE NAME: Akynzeo (Helsinn)
- INDICATIONS: Acute and delayed nausea and vomiting associated with cancer chemotherapy
- SYNONYM: NEPA
- CLASS: Neurokinin 1 receptor antagonist (netupitant), Serotonin type 3 receptor antagonist (palonosetron)
- HALF-LIFE: 40 hours
FDA APPROVAL DATE: 10/10/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric